According to the Public Relations of Razi Institute, Dr. Hamidreza Inanloo , Director General of the National FDA stated: Based on the evaluation of the results obtained from clinical studies of booster dose of Razi Cov Pars vaccine in people 18 years and older, the vaccine showed the necessary immunogenicity.
Dr. Inanloo dded: "The results of the study showed that the booster dose of Razi Cov Pars vaccine was effective in people who received initial doses of inactivated vaccines (Sinopharm, Barakat), viral vector (Sputnik and AstraZeneca) and recombinant protein (Razi Cov Pars)." Razi Cov Pars vaccine is the most effective in people who have received inactivated vaccines as the initial doses.